German pharmaceutical company Boehringer Ingelheim plans to spend 25 billion euros on the research and development of new products over the next five years. A further 7 billion euros is earmarked for investments in new production technologies, the company announced on Wednesday when it presented its half-year figures.
In its Human Pharma business unit, the company increased its sales in the first six months of 2022 by 11.8 percent year-on-year (currency-adjusted) to 8.4 billion euros. Drivers of sales were medicines for the treatment of cardiovascular and metabolic diseases, as well as respiratory disorders. The Animal Health business unit grew by 1.2 percent to 2.4 billion euros.
The Animal Health business was impacted by inflation and supply chain constraints, among other factors, the company said.
“Although we expect economic uncertainties to persist in the second half of the year, we remain confident that we can achieve our goals for 2022,” said Chief Financial Officer Michael Schmelmer.
Notice: No person, organization and/or company shall disseminate or broadcast the above article on Xinhua Silk Road website without prior permission by Xinhua Silk Road.
A single purchase
